Affinia Therapeutics to Present Preclinical Data on Novel AAV Capsids at the 30th European Society of Gene and Cell Therapy 2023 Annual Congress
WALTHAM, Mass. October 24, 2023
Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and prevalent devastating diseases, today announced that the company will present preclinical data on its novel AAV capsids for skeletal muscle, cardiac muscle, and central nervous system (CNS) in a poster session at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, being held October 24-27, 2023, in Brussels, Belgium.
The poster presentation details are listed below and the full program can be found on the ESGCT website at www.esgctcongress.com.
Title: Engineered AAV capsids with significantly improved muscle and CNS tropism plus reduced liver and DRG expression compared to AAV9
Abstract Number: P084
Date: October 25, 2023, 6:15-7:30 PM CEST and October 26, 2023, 7:30-8:30 PM CEST
Presenter: John Reece-Hoyes, Ph.D., Senior Director, Head of Vector Biology, Affinia
About Affinia TherapeuticsAffinia Therapeutics is pioneering a shift to a new class of rationally designed gene therapies that treat rare and prevalent devastating diseases. Affinia Therapeutics’ proprietary Affinia Rationally designed Therapeutics (ART) platform consists of three pillars intended to synergistically improve the efficacy, safety, and manufacturability of adeno-associated virus (AAV)-based gene therapies through the development of next-generation capsids, promoters, and manufacturing approaches. For more information, visit https://www.affiniatx.com.
Contact Information
Investors: investors@affiniatx.com
Media: Kathy Vincent, media@affiniatx.com